Superior Efficacy of Besifovir in Reducing Hepatocellular Carcinoma Risk Compared to Tenofovir in Chronic Hepatitis B Patients: A Nationwide Cohort Study

Yoon E Shin, Jae Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim · 2026

Read Superior Efficacy of Besifovir in Reducing Hepatocellular Carcinoma Risk Compared to Tenofovir in Chronic Hepatitis B Patients: A Nationwide Cohort Study by Yoon E Shin, Jae Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13659106.txt.

Description

Yoon Shin and five colleagues compare two hepatitis B drugs on the outcome patients fear most: liver cancer. Besifovir is a newer option for chronic hepatitis B, while tenofovir has a long track record, and besifovir's long-term effect on cancer risk was unproven. Using Korean national insurance records covering more than thirty thousand patients, the team matched besifovir users with similar tenofovir users to make the comparison fair.

Liver cancer developed less often in the besifovir group, with cirrhosis tracked as a second outcome. Because the data come from routine care nationwide rather than a selected trial population, the result carries real-world weight, though records-based studies cannot erase every difference between groups. For doctors choosing between two daily antivirals meant to be taken for years, cancer risk is exactly the kind of long-horizon evidence that should steer the choice.

Catalog record

CREATORYoon E Shin, Jae Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25157
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13659106

Browse the full library · About the Tower of Babel